Titan Pharmaceuticals Inc (TTNP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) has a cash flow conversion efficiency ratio of -0.244x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-680.00K) by net assets ($2.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Titan Pharmaceuticals Inc (TTNP) balance sheet quality index to measure how much of total assets are equity-financed.
Titan Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TTNP cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Titan Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Titan Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eo2 Société Anonyme
PA:ALEO2
|
-0.035x |
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
-0.010x |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
-0.054x |
|
Djasa Ubersakti Tbk
JK:PTDU
|
-5.449x |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
3.252x |
|
Digitalist Group Oyj
HE:DIGIGR
|
0.017x |
|
Scandinavian Brake Systems A/S
CO:SBS
|
-0.012x |
|
The North American Income Trust plc
LSE:NAIT
|
0.019x |
Annual Cash Flow Conversion Efficiency for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Titan Pharmaceuticals Inc from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see Titan Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.44 Million | $-3.88 Million | -1.590x | -48.93% |
| 2023-12-31 | $6.64 Million | $-7.09 Million | -1.068x | +82.22% |
| 2022-12-31 | $1.36 Million | $-8.18 Million | -6.004x | -290.52% |
| 2021-12-31 | $5.14 Million | $-7.90 Million | -1.537x | +68.44% |
| 2020-12-31 | $3.53 Million | $-17.20 Million | -4.871x | +54.81% |
| 2019-12-31 | $1.43 Million | $-15.45 Million | -10.778x | -773.27% |
| 2018-12-31 | $6.83 Million | $-8.43 Million | -1.234x | +91.89% |
| 2017-12-31 | $857.00K | $-13.04 Million | -15.214x | -3288.97% |
| 2016-12-31 | $13.19 Million | $6.29 Million | 0.477x | +144.67% |
| 2015-12-31 | $6.99 Million | $-7.47 Million | -1.068x | -56.82% |
| 2014-12-31 | $8.61 Million | $-5.87 Million | -0.681x | +59.96% |
| 2013-12-31 | $5.76 Million | $-9.80 Million | -1.701x | -2050.04% |
| 2012-12-31 | $-23.13 Million | $1.83 Million | -0.079x | -110.98% |
| 2011-12-31 | $-20.08 Million | $-14.48 Million | 0.721x | -6.29% |
| 2010-12-31 | $-6.05 Million | $-4.66 Million | 0.769x | -97.05% |
| 2009-12-31 | $-207.00K | $-5.41 Million | 26.121x | +285.55% |
| 2008-12-31 | $1.80 Million | $-25.34 Million | -14.078x | -2364.45% |
| 2007-12-31 | $26.59 Million | $-15.19 Million | -0.571x | +50.72% |
| 2006-12-31 | $11.65 Million | $-13.50 Million | -1.159x | +16.04% |
| 2005-12-31 | $16.60 Million | $-22.92 Million | -1.381x | -101.83% |
| 2004-12-31 | $34.95 Million | $-23.91 Million | -0.684x | -18.17% |
| 2003-12-31 | $45.67 Million | $-26.44 Million | -0.579x | -42.27% |
| 2002-12-31 | $71.98 Million | $-29.29 Million | -0.407x | -200.24% |
| 2001-12-31 | $101.37 Million | $-13.74 Million | -0.136x | -19.42% |
| 2000-12-31 | $115.98 Million | $-13.16 Million | -0.113x | +52.62% |
| 1999-12-31 | $45.50 Million | $-10.90 Million | -0.240x | +80.62% |
| 1998-12-31 | $10.60 Million | $-13.10 Million | -1.236x | -420.28% |
| 1997-12-31 | $18.40 Million | $7.10 Million | 0.386x | +145.02% |
| 1996-12-31 | $12.60 Million | $-10.80 Million | -0.857x | -145.85% |
| 1995-12-31 | $-4.60 Million | $-8.60 Million | 1.870x | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.